Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.

Biotechnology

Pharmaceutical

Therapeutics

Cybrexa Therapeutics

Cybrexa Therapeutics' headquarters in New Haven, CT, United States

Per Hellsund

John Houston

Victor Facchini

Jaya Gautam

Vishwas Paralkar

Ranjit Bindra

Mike Needle

Description

People (6)

Per Hellsund

Ranjit Bindra

Vishwas Paralkar

Sophia Gayle

Patricia Bourassa

Jane Bechtold

Jobs